BR112014026730A2 - conjugados fármaco-ligante de dr5 - Google Patents

conjugados fármaco-ligante de dr5

Info

Publication number
BR112014026730A2
BR112014026730A2 BR112014026730A BR112014026730A BR112014026730A2 BR 112014026730 A2 BR112014026730 A2 BR 112014026730A2 BR 112014026730 A BR112014026730 A BR 112014026730A BR 112014026730 A BR112014026730 A BR 112014026730A BR 112014026730 A2 BR112014026730 A2 BR 112014026730A2
Authority
BR
Brazil
Prior art keywords
linker
drug
moiety
conjugates
unit
Prior art date
Application number
BR112014026730A
Other languages
English (en)
Inventor
Yada Ayumi
Ichikawa Kimihisa
Ohtsuka Toshiaki
Original Assignee
Daiichi Sankyo Co Ltd
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Seattle Genetics Inc filed Critical Daiichi Sankyo Co Ltd
Publication of BR112014026730A2 publication Critical patent/BR112014026730A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “conjugados fármaco-ligante de dr5” são fornecidos conjugados fármaco-ligante que possuem uma porção de ligação de dr5 anexada por meio de grupos de ligação e/ou espaçadores a um agente terapêutico que são eficazes no tratamento de vários cânceres. em algumas modalidades, o conjugado ligante-fármaco possui a fórmula: l-(lu-d)p, em que l é uma unidade de ligante, lu é uma unidade vinculadora e d é uma unidade de fármaco (ou agente citotóxico). o subscrito p é um número inteiro de 1 a 20. consequentemente, os conjugados fármaco-ligante compreendem uma unidade de ligante ligada covalentemente a pelo menos uma unidade de fármaco. as unidades de fármaco podem ser ligadas covalentemente diretamente ou por meio de uma unidade vinculadora (-lu-). a unidade de ligante é um agente de ligação de dr5 como, por exemplo, um anticorpo anti-dr5.
BR112014026730A 2012-04-24 2013-04-23 conjugados fármaco-ligante de dr5 BR112014026730A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637808P 2012-04-24 2012-04-24
PCT/US2013/037861 WO2013163229A1 (en) 2012-04-24 2013-04-23 Dr5 ligand drug conjugates

Publications (1)

Publication Number Publication Date
BR112014026730A2 true BR112014026730A2 (pt) 2017-07-11

Family

ID=49380328

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026730A BR112014026730A2 (pt) 2012-04-24 2013-04-23 conjugados fármaco-ligante de dr5

Country Status (10)

Country Link
US (2) US20130280282A1 (pt)
EP (1) EP2841103A4 (pt)
JP (1) JP2015516401A (pt)
KR (1) KR20150003836A (pt)
CN (1) CN104619339A (pt)
BR (1) BR112014026730A2 (pt)
CA (1) CA2869846A1 (pt)
RU (1) RU2014146951A (pt)
TW (1) TW201347775A (pt)
WO (1) WO2013163229A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201804788XA (en) 2012-10-11 2018-07-30 Daiichi Sankyo Co Ltd Antibody-drug conjugate
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
ES2703903T3 (es) 2013-12-25 2019-03-13 Daiichi Sankyo Co Ltd Conjugado de fármaco-anticuerpo anti-trop2
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
EP3122376A4 (en) 2014-03-27 2017-12-20 The Brigham and Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
WO2015155998A1 (en) * 2014-04-10 2015-10-15 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
JP6612738B2 (ja) 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
RU2020123953A (ru) * 2014-12-09 2020-09-18 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
CN111620862A (zh) * 2014-12-09 2020-09-04 艾伯维公司 Bcl-xl抑制性化合物和包括其的抗体药物缀合物
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
KR20180021723A (ko) 2015-06-29 2018-03-05 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 선택적 제조 방법
EP3442979A4 (en) * 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
TW201828993A (zh) 2016-12-12 2018-08-16 日商第一三共股份有限公司 抗體－藥物結合物與免疫檢查點抑制劑之組合
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
CN110152014B (zh) * 2018-02-13 2022-09-27 烟台市和元艾迪斯生物医药科技有限公司 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
WO2019157772A1 (zh) * 2018-02-13 2019-08-22 和元生物技术（上海）股份有限公司 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
DK3794042T3 (da) 2018-05-18 2024-04-15 Daiichi Sankyo Co Ltd Anti-muc1-exatecet-antistof-lægemiddelkonjugat
US20200407440A1 (en) 2019-04-24 2020-12-31 Magenta Therapeutics, Inc. Amatoxin antibody-drug conjugates and uses thereof
WO2023081230A1 (en) * 2021-11-03 2023-05-11 Adcentrx Therapeutics Inc. Novel auristatin analogs and immunoconjugates thereof
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
DE60134962D1 (de) * 2000-03-03 2008-09-04 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
EP3120861B1 (en) * 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
AU2005256113B2 (en) * 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
WO2007103288A2 (en) * 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
WO2008072723A1 (ja) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
CN101932608A (zh) * 2007-11-30 2010-12-29 葛兰素集团有限公司 抗原结合构建体
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc LIGAND-DRUG CONJUGATES DR5
DK2636736T3 (en) * 2010-10-29 2016-07-04 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
EA038979B1 (ru) * 2011-03-31 2021-11-17 Адс Терапьютикс Са Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты
RS57259B1 (sr) * 2012-12-24 2018-08-31 Abbvie Inc Prolaktin receptor vezujući proteini i njihova upotreba

Also Published As

Publication number Publication date
US20150079114A1 (en) 2015-03-19
JP2015516401A (ja) 2015-06-11
TW201347775A (zh) 2013-12-01
KR20150003836A (ko) 2015-01-09
US20130280282A1 (en) 2013-10-24
WO2013163229A1 (en) 2013-10-31
CN104619339A (zh) 2015-05-13
EP2841103A4 (en) 2015-12-30
RU2014146951A (ru) 2016-06-10
CA2869846A1 (en) 2013-10-31
EP2841103A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
BR112014026730A2 (pt) conjugados fármaco-ligante de dr5
PH12019502278A1 (en) Conjugation of a cytotoxic drug with bis-linkage
EA033456B1 (ru) Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры
JOP20210073A1 (ar) مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
CY1124166T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
BR112015023333A8 (pt) pirrolbenzodiazepinas e conjugados dos mesmos
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
UA115517C2 (uk) Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
AU2012253610A8 (en) Compositions and methods for treating cancer
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
MX2021003295A (es) Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
NZ719369A (en) Conjugates of cell binding molecules with cytotoxic agents
IN2013DE03280A (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]